{"doi":"10.1056/nejmoa2305032","title":"Trial of Solanezumab in Preclinical Alzheimer’s Disease","abstract":"Trials of monoclonal antibodies that target various forms of amyloid at different stages of Alzheimer’s disease have had mixed results. Download a PDF of the Research Summary. We tested solanezumab, which targets monomeric amyloid, in a phase 3 trial involving persons with preclinical Alzheimer’s disease. Persons 65 to 85 years of age with a global Clinical Dementia Rating score of 0 (range, 0 to 3, with 0 indicating no cognitive impairment and 3 severe dementia), a score on the Mini–Mental State Examination of 25 or more (range, 0 to 30, with lower scores indicating poorer cognition), and elevated brain amyloid levels on 18F-florbetapir positron-emission tomography (PET) were enrolled. Participants were randomly assigned in a 1:1 ratio to receive solanezumab at a dose of up to 1600 mg intravenously every 4 weeks or placebo. The primary end point was the change in the Preclinical Alzheimer Cognitive Composite (PACC) score (calculated as the sum of four z scores, with higher scores indicating better cognitive performance) over a period of 240 weeks. A total of 1169 persons underwent randomization: 578 were assigned to the solanezumab group and 591 to the placebo group. The mean age of the participants was 72 years, approximately 60% were women, and 75% had a family history of dementia. At 240 weeks, the mean change in PACC score was −1.43 in the solanezumab group and −1.13 in the placebo group (difference, −0.30; 95% confidence interval, −0.82 to 0.22; P=0.26). Amyloid levels on brain PET increased by a mean of 11.6 centiloids in the solanezumab group and 19.3 centiloids in the placebo group. Amyloid-related imaging abnormalities (ARIA) with edema occurred in less than 1% of the participants in each group. ARIA with microhemorrhage or hemosiderosis occurred in 29.2% of the participants in the solanezumab group and 32.8% of those in the placebo group. Solanezumab, which targets monomeric amyloid in persons with elevated brain amyloid levels, did not slow cognitive decline as compared with placebo over a period of 240 weeks in persons with preclinical Alzheimer’s disease. (Funded by the National Institute on Aging and others; A4 ClinicalTrials.gov number, NCT02008357.) QUICK TAKE VIDEO SUMMARYSolanezumab in Preclinical Alzheimer’s Disease 02:05","journal":"New England Journal of Medicine","year":2023,"id":314806,"datarank":4.858307313824888,"base_score":5.968707559985366,"endowment":5.968707559985366,"self_citation_contribution":0.895306133997805,"citation_network_contribution":3.9630011798270823,"self_endowment_contribution":0.895306133997805,"citer_contribution":3.9630011798270823,"corpus_percentile":null,"corpus_rank":null,"citation_count":390,"citer_count":100,"citers_with_citation_signal":100,"citers_with_endowment":100,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9505,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT02008357"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":51716,"name":"Michael Donohue","orcid":"0000-0001-6026-2238","position":1,"is_corresponding":false},{"id":226625,"name":"Rema Raman","orcid":"0000-0002-4096-6390","position":2,"is_corresponding":false},{"id":34920,"name":"Michael S. Rafii","orcid":"0000-0003-2640-2094","position":3,"is_corresponding":false},{"id":33059,"name":"Keith Johnson","orcid":"0000-0002-8578-5921","position":4,"is_corresponding":false},{"id":230035,"name":"Colin L. Masters","orcid":"0000-0003-3072-7940","position":5,"is_corresponding":false},{"id":235262,"name":"Christopher H. van Dyck","orcid":"0000-0003-1779-097X","position":6,"is_corresponding":false},{"id":55002,"name":"Takeshi Iwatsubo","orcid":"0000-0003-1160-8129","position":7,"is_corresponding":false},{"id":313455,"name":"Gad A. Marshall","orcid":"0000-0002-9096-2355","position":8,"is_corresponding":false},{"id":232960,"name":"R. Yaari","orcid":"0000-0002-3149-8361","position":9,"is_corresponding":false},{"id":868905,"name":"Michele Mancini","orcid":"0000-0003-0845-2813","position":10,"is_corresponding":false},{"id":234516,"name":"Karen C. Holdridge","orcid":null,"position":11,"is_corresponding":false},{"id":1015357,"name":"Michael Case","orcid":null,"position":12,"is_corresponding":false},{"id":618063,"name":"John R. Sims","orcid":"0009-0009-0168-9050","position":13,"is_corresponding":false},{"id":229340,"name":"Paul Aisen","orcid":null,"position":14,"is_corresponding":false},{"id":55000,"name":"Reisa A. Sperling","orcid":"0000-0003-1535-6133","position":0,"is_corresponding":true}],"reference_count":36,"raw_metadata":null,"created_at":"2026-07-19T01:06:02.898877Z","pmid":"37458272","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}